$290 Million is the total value of Abingworth LLP's 17 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $82,124,000 | -25.8% | 4,168,718 | 0.0% | 28.36% | -25.1% | |
| PHAT | Phathom | $45,057,000 | +12.8% | 1,203,135 | 0.0% | 15.56% | +13.8% | |
| Spruce Bio | $29,738,000 | -31.0% | 1,792,518 | 0.0% | 10.27% | -30.3% | ||
| ACET | New | Adicet | $20,968,000 | – | 1,615,385 | +100.0% | 7.24% | – |
| VRNA | Veronasponds adr | $20,274,000 | +19.7% | 2,457,499 | 0.0% | 7.00% | +20.9% | |
| SIEN | Sientra | $17,358,000 | +86.6% | 2,390,843 | 0.0% | 6.00% | +88.5% | |
| NCNA | Nucanaads | $16,567,000 | +10.7% | 3,333,333 | 0.0% | 5.72% | +11.8% | |
| XCUR | Exicure | $15,140,000 | +22.6% | 6,977,000 | 0.0% | 5.23% | +23.8% | |
| SRRA | Sierra Oncology | $14,722,000 | +5.9% | 871,125 | 0.0% | 5.08% | +6.9% | |
| SLNO | Soleno | $12,981,000 | -34.7% | 10,302,602 | 0.0% | 4.48% | -34.1% | |
| PRTK | Paratek | $7,330,000 | +12.5% | 1,041,131 | 0.0% | 2.53% | +13.6% | |
| MTEM | Molecular Templates | $2,512,000 | +33.3% | 200,000 | 0.0% | 0.87% | +34.8% | |
| XFOR | New | X4 Pharma | $1,956,000 | – | 229,885 | +100.0% | 0.68% | – |
| AGLE | Aeglea | $1,895,000 | +0.1% | 240,500 | 0.0% | 0.65% | +0.9% | |
| CBAY | Cymabay | $595,000 | -20.9% | 131,036 | 0.0% | 0.20% | -20.2% | |
| OBSV | Obseva | $286,000 | +57.1% | 87,999 | 0.0% | 0.10% | +59.7% | |
| HSGX | Ocugen | $48,000 | +269.2% | 7,111 | 0.0% | 0.02% | +325.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.